Gleevec
- All
- News
-
Sun Pharma First-Quarter Profit Boosted By Gleevec Generic
Sun Pharmaceutical Industries Ltd, India's largest drugmaker, reported a quarterly profit that beat analysts' estimates, helped by its exclusive launch of the first generic version of leukaemia drug Gleevec in the United States.
-
Drug Defies A Rare Form Of Cancer - And Market Logic
When the drug company Novartis launched its breakthrough cancer medicine, Gleevec, in 2001, the list price was $26,400 a year. The company's chief executive acknowledged it was expensive, calling it an "uphill battle to win understanding for our decision."
-
Sun Pharma Bets on Cut-Price Gleevec To Boost US Sales
Sun Pharma launched a generic version of Novartis's leukaemia drug Gleevec on Monday in the United States and hopes to poach a third of sales in six months by pricing the copycat some 30 per cent cheaper, Sun's North American chief executive said.
-
Sun Pharma Extends Rally on Anti-Cancer Drug Approval
Sun Pharma shares have underperformed the broader Nifty in the last three months as the company is struggling with issues at its Halol manufacturing facility, Ranbaxy integration as well as pricing pressure in the United States, the company's largest market.
-
Sun Pharma Gets US Regulator's Nod for Cancer Treatment Drug
Drug major Sun Pharmaceutical Industries on Friday said one of its subsidiaries has received approval of the US Food and Drug Administration (FDA) to manufacture and market generic version of Novartis' Gleevec, used in treatment of cancer, in America.
-
Sun Pharma Surges Over 6% on New Drug Approval
Sun Pharma is expected to commercially launch the product on February 1, 2016. "Under the terms of a settlement agreement with Novartis, the Sun Pharma subsidiary is permitted to launch its version of generic Gleevec in the United States on February 1, 2016," the company said.
-
Piramal to raise R&D spend for cancer drugs' trials
Drugmaker Piramal Healthcare's research and development (R&D) spend will significantly rise this fiscal year as it looks to initiate the second phase of clinical trials for at least two oncology molecules
-
Sun Pharma First-Quarter Profit Boosted By Gleevec Generic
Sun Pharmaceutical Industries Ltd, India's largest drugmaker, reported a quarterly profit that beat analysts' estimates, helped by its exclusive launch of the first generic version of leukaemia drug Gleevec in the United States.
-
Drug Defies A Rare Form Of Cancer - And Market Logic
When the drug company Novartis launched its breakthrough cancer medicine, Gleevec, in 2001, the list price was $26,400 a year. The company's chief executive acknowledged it was expensive, calling it an "uphill battle to win understanding for our decision."
-
Sun Pharma Bets on Cut-Price Gleevec To Boost US Sales
Sun Pharma launched a generic version of Novartis's leukaemia drug Gleevec on Monday in the United States and hopes to poach a third of sales in six months by pricing the copycat some 30 per cent cheaper, Sun's North American chief executive said.
-
Sun Pharma Extends Rally on Anti-Cancer Drug Approval
Sun Pharma shares have underperformed the broader Nifty in the last three months as the company is struggling with issues at its Halol manufacturing facility, Ranbaxy integration as well as pricing pressure in the United States, the company's largest market.
-
Sun Pharma Gets US Regulator's Nod for Cancer Treatment Drug
Drug major Sun Pharmaceutical Industries on Friday said one of its subsidiaries has received approval of the US Food and Drug Administration (FDA) to manufacture and market generic version of Novartis' Gleevec, used in treatment of cancer, in America.
-
Sun Pharma Surges Over 6% on New Drug Approval
Sun Pharma is expected to commercially launch the product on February 1, 2016. "Under the terms of a settlement agreement with Novartis, the Sun Pharma subsidiary is permitted to launch its version of generic Gleevec in the United States on February 1, 2016," the company said.
-
Piramal to raise R&D spend for cancer drugs' trials
Drugmaker Piramal Healthcare's research and development (R&D) spend will significantly rise this fiscal year as it looks to initiate the second phase of clinical trials for at least two oncology molecules
